YHB Investment Advisors Inc. increased its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 13.0% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 30,666 shares of the medical instruments supplier’s stock after purchasing an additional 3,533 shares during the period. Becton Dickinson and makes up approximately 1.2% of YHB Investment Advisors Inc.’s holdings, making the stock its 24th largest position. YHB Investment Advisors Inc.’s holdings in Becton Dickinson and were worth $6,910,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. IMS Capital Management bought a new position in Becton Dickinson and in the 3rd quarter valued at $29,000. Acropolis Investment Management LLC bought a new position in shares of Becton Dickinson and in the 3rd quarter valued at about $101,000. Almanack Investment Partners LLC. bought a new position in shares of Becton Dickinson and in the 2nd quarter valued at about $105,000. Truvestments Capital LLC bought a new position in shares of Becton Dickinson and in the 3rd quarter valued at about $105,000. Finally, Bridgeworth LLC bought a new position in Becton Dickinson and during the second quarter worth about $131,000. 83.77% of the stock is owned by institutional investors and hedge funds.

Several research analysts have commented on BDX shares. Morgan Stanley boosted their price objective on shares of Becton Dickinson and from $250.00 to $280.00 and gave the company an “equal weight” rating in a research report on Thursday, October 4th. Barclays initiated coverage on shares of Becton Dickinson and in a report on Monday, October 15th. They set an “equal weight” rating and a $278.00 price objective on the stock. TheStreet lowered shares of Becton Dickinson and from a “b+” rating to a “c+” rating in a report on Friday, December 7th. UBS Group initiated coverage on shares of Becton Dickinson and in a report on Tuesday, November 27th. They issued a “neutral” rating and a $260.00 target price on the stock. Finally, KeyCorp upped their target price on shares of Becton Dickinson and from $264.00 to $273.00 and gave the stock an “overweight” rating in a report on Thursday, November 8th. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $251.85.

NYSE BDX traded down $0.58 on Friday, hitting $228.87. The stock had a trading volume of 49,848 shares, compared to its average volume of 1,235,191. Becton Dickinson and Co has a 52-week low of $208.62 and a 52-week high of $265.87. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.03 and a quick ratio of 0.69. The stock has a market capitalization of $61.02 billion, a PE ratio of 20.79, a P/E/G ratio of 1.63 and a beta of 1.21.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $2.93. The firm had revenue of $4.40 billion for the quarter, compared to analysts’ expectations of $4.36 billion. Becton Dickinson and had a net margin of 1.47% and a return on equity of 13.88%. The business’s quarterly revenue was up 39.0% on a year-over-year basis. During the same quarter last year, the company posted $2.40 EPS. On average, research analysts anticipate that Becton Dickinson and Co will post 12.11 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Monday, December 31st. Shareholders of record on Monday, December 10th were issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 1.35%. The ex-dividend date was Friday, December 7th. This is a positive change from Becton Dickinson and’s previous quarterly dividend of $0.75. Becton Dickinson and’s dividend payout ratio (DPR) is 27.97%.

In other news, SVP Charles R. Bodner sold 2,080 shares of Becton Dickinson and stock in a transaction dated Friday, November 16th. The shares were sold at an average price of $245.83, for a total transaction of $511,326.40. Following the sale, the senior vice president now owns 4,497 shares of the company’s stock, valued at approximately $1,105,497.51. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP James W. Borzi sold 5,887 shares of Becton Dickinson and stock in a transaction dated Friday, November 30th. The shares were sold at an average price of $252.37, for a total transaction of $1,485,702.19. Following the sale, the executive vice president now directly owns 6,013 shares in the company, valued at approximately $1,517,500.81. The disclosure for this sale can be found here. In the last three months, insiders sold 81,795 shares of company stock worth $19,571,318. Insiders own 0.12% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Becton Dickinson and Co (BDX) Shares Bought by YHB Investment Advisors Inc.” was originally published by Daily Political and is the property of of Daily Political. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2019/01/11/becton-dickinson-and-co-bdx-shares-bought-by-yhb-investment-advisors-inc.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Story: What is Depreciation?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.